Zalifrelimab is under clinical development by Agenus and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zalifrelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zalifrelimab overview

AGEN-1884 (zalifrelimab) is under development for the treatment of pancreatic ductal adenocarcinoma, metastatic soft tissue sarcomas, solid tumors, metastatic angiosarcoma, non-small cell lung cancer (second line therapy), cervical cancer, advanced cutaneous squamous cell carcinoma, melanoma, non-muscle invasive bladder cancer, prostate cancer and lymphoma. It acts by targeting CTLA-4. The drug candidate is a lead compound and checkpoint modulator antibody. It is administered through intravenous and intravesical route. The drug candidate is based on the retrocyte display technology. It was also under development for the treatment of non-small cell lung cancer (first line therapy).

Agenus overview

Agenus is a clinical-stage immuno-oncology company that discovers, develops, and commercializes a wide range of immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company collaborates with several pharmaceutical companies such as GSK, Incyte, and Merck. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.

For a complete picture of Zalifrelimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.